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Abstract 
Despite the advancements in bone transplantation operations, inflammation is still a serious problem that threatens human 
health at the post-implantation period. Conventional antibiotic therapy methods may lead to some side effects such as 
ototoxicity and nephrotoxicity, especially when applied in high doses. Therefore, local drug delivery systems play a vital role 
in bone disorders due to the elimination of the disadvantages introduced by conventional methods. In the presented study, it 
was aimed to develop Vancomycin (VC) and Gentamicin (GC) loaded chitosan-montmorillonite nanoclay composites 
(CS/MMT) to provide required antibiotic doses to combat post-implantation infection. CS/MMT nanocomposite formation 
was supplied by microfluidizer homogenization and spherical drug carrier nanoparticles were obtained by electrospraying 
technique. Three factors; voltage, distance and flowrate were varied to fabricate spherical nanoparticles with uniform size. 
Emprical model was developed to predict nanosphere size by altering process variables. Nanospheres were characterized in 
terms of morphology, hydrodynamic size, zeta potential, drug encapsulation efficiency and release profile. Drug loaded 
nanospheres have been successfully produced with a size range of 180-350 nm. Nanocomposite drug carriers showed  high 
encapsulation efficiency (80-95%) and prolonged release period when compared to bare chitosan nanospheres. The drug 
release from nanocomposite carriers was monitored by diffusion mechanism up to 30 days. The in vitro release medium of 
nanospheres showed strong antimicrobial activity against gram-positive S. aureus and gram-negative E. coli bacteria. 
Furthermore, it was found that the nanospheres did not show any cytotoxic effect to fibroblast (NIH/3T3) and osteoblast 
(SaOS-2) cell lines. The results demonstrated that the prepared composite nanospheres can be a promising option for bone 
infection prevention at the post implantation period. 
Keywords: nanocomposite, drug delivery, antibiotic, bone, infection 
 
1. Introduction 
There has been a significant increase in the bone disorders 
due to the population aging and the sedentary lifestyle of the 
people today. Musculoskeletal problems, severe bone tissue 
degeneration and advanced inflammatory problems cannot be 
treated with a medication. Consequently, there is an 
increasing demand for bone replacement materials to ensure 
adequate support during the healing process and promote 
new bone growth. However, inflammation is still a drawback 
of these operations which should immediately be treated to 
prevent the biofilm formation on the implant surface. To 
address this issue, local controlled antibiotic releasing 
systems can be an alternative to conventional methods to 
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prevent the inflammation at the bone defects. The site-
specific drug delivery systems supply an effective delivery 
and prevent the side effects caused by high dosage of the 
antibiotics such as toxicity and nephrotoxicity1.  
The material selection to achieve sustained release is a 
challenging issue. Therefore, a wide range of materials has 
been used to adjust the release rate regarding the specified 
criteria for each system. Thus, natural polymer-based 
nanoparticles can circumvent these issues due to their 
biocompatibility, biodegradability and the ease in 
processability. Chitosan (CS) is a natural aminoglycosidic 
polymer that has been commonly used in drug delivery 
systems according to its outstanding properties. The active 
amino groups of positively charged chitosan provide reactive 
sites for various groups that make it an ideal candidate for 
carrying any types of drugs.  Chitosan-based carrier systems 
have been evaluated and showed promising results in local 
antibiotic delivery in forms of the hydrogel, bead or film 2,3,4. 
However, it shows rapid degradation profile and high 
swelling degree. Thus, it requires a modification to improve 
its stability which is substantial to design a rate-controlled 
drug delivery. In order to overcome these drawbacks, anionic 
excipients, crosslinking or composite formation can be 
preferred to harden the polymer matrix and prolong the drug 
release period.  
Recently, composite formation with nanofillers has 
attained a great interest according to the superior properties 
as compared to biopolymer itself. Polymer-clay 
nanocomposites are the hybrid materials composed of the 
synergistic effect of the organic polymer matrix and 
nanoscale organophilic clay fillers. Montmorillonite (MMT) 
is a smectite group of minerals that is the most commonly 
used nanofiller in biopolymeric composite systems. Layered 
structure of the MMT is suitable for reinforcement purposes 
and provides a tortuous pathway for drug delivery. Studies 
showed that MMT nano-reinforcement is a promising 
approach in drug delivery systems in order to overcome 
obstructions regarding characteristics of biopolymers. Recent 
literature findings indicated that chitosan/montmorillonite 
(CS/MMT) nanocomposite systems can ensure improved 
cationic and anionic drug stability, enhanced drug 
permeability and extended drug release profile 5,6,7,8. 
Generally conventional homogenization techniques 
(sonication systems, twin screw extrusion) were used to 
disperse nanoparticles in polymer matrix. Recently, 
microfluidization systems have come into prominence as 
high-pressure homogenization to obtain efficent dispersion in  
polymer-inorganic of polymer-bioactive component systems. 
Microfluidizer systems also overcome the limitations of 
conventional homogenization systems such as limited 
dispersion level, change in viscosity of biopolymers and 
possible disruption ultrasonication probe and leakage of 
metal in polymer solution. The sandwich structure of MMT 
offers expandable clay layers that give homogenous 
properties to the composite system if it could be well-
dispersed in the polymer matrix. Thus, high-pressure 
microfluidizer (MF) homogenization can be used for 
dispersion of individual clay platelets in chitosan matrix for 
nanocomposite formation. However, there are still limited 
studies regarding the nanocomposite formation via 
microfluidizer homogenization 9,10. 
Therefore, the aim of this study is to develop a 
chitosan/montmorillonite composite system for the delivery 
of Gentamicin (GC) and Vancomycin (VC) antibiotics which 
are commonly recommended for bone infection treatment. 
CS/MMT nanocomposite was formed with microfluidization 
technique and electrosprayed to obtain spherical 
nanoparticles. The nanofiller dispersion level in a chitosan 
matrix was determined with X-Ray Diffraction (XRD) 
patterns. Two-level full factorial design was used to optimize 
electrospray process variables. The fabricated nanospheres 
were characterized with Scanning Electron Microscopy 
(SEM), Atomic Force Microscopy (AFM), Fourier 
Transform Infrared Spectroscopy (FT-IR), Dynamic Light 
Scattering (DLS), zeta potential and encapsulation efficiency 
studies. In vitro GC and VC release profiles were determined 
for sub-acute osteomyelitis treatment. The dominant 
mechanism in the drug delivery was determined with the 
appropriate kinetic models. The antibacterial activities of 
nanospheres against S. aureus and E. coli were determined 
with the agar diffusion method. The in vitro cytotoxicity of 
the nanospheres were determined with NIH/3T3 and SaOS-2 
cell lines.  
2. Materials and Methods 
2.1. Materials 
High molecular weight chitosan (Sigma-Aldrich, 
Germany, Cat. No. 419419), organically modified 
montmorillonite (Cloisite 10A, Southern Clay Products Inc.) 
and glacial acetic acid (Analytical grade, Merck) were used 
for solution preparation. Gentamicin (Genta, IE Ulagay) and 
vancomycin (Anko-L, Mustafa Nevzat) were selected as 
model antibiotics. Phosphate buffer saline (PBS) solution 
(pH=7.4, Sigma-Aldrich) was used for DLS, zeta potential 
and in vitro drug release studies. 
The WST-1 assay (Biovision Inc.), Dulbecco’s Modified 
Eagle Medium (DMEM, Capricorn), penicillin and 
streptomycin antibiotic solution (Capricorn), fetal bovine 
serum (FBS, Capricorn) were used for the in vitro 
cytotoxicity determination.  
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2.2. Preparation and Characterization  of CS/MMT 
Nanocomposite Solution  
Briefly, 2% (w/v) CS was dissolved in 90% (v/v) acetic 
acid solution and stirred overnight. MMT nanoclay (3% w/w 
chitosan) was dispersed in distilled water, stirred for 24 h at 
room temperature and added to polymer solution dropwise, 
followed by a continuous stirring. The solution was injected 
to the Z type interaction chamber of the microfluidizer 
(Microfluidics LV1, USA) with 10,000 psi, 3 and 5 passes of 
working conditions to obtain CS/MMT nanocomposite 
structure.  
Homogenized solutions were prefreezed, lyophilized and 
stored for further characterization studies. Samples were 
analyzed with XRD analysis (Philips X’PertPro MRD) to 
determine the dispersion level of clay platelets in polymer 
matrix. Diffraction patterns were determined at 40 kV using 
Cu-Kα radiation (λ=1.54 Å). Intensities were recorded in a 
range of 2-30° (2θ) with a scanning rate of 0.139°/sec. The d-
spacing value that indicates the distance between the 
nanoclay silicate layers was calculated with the Bragg’s law. 
The dispersion of MMT layers and the exfoliated structure 
of platelets in polymer matrix was also observed with STEM 
analysis. CS/MMT solution was dropped on Cu-grids (UC-A 
on Lacey, 400 mesh TED PELLA INC.) and dried at ambient 
conditions before analysis. 
The functional groups in CS, MMT and CS/MMT 
nanocomposite were determined with FT-IR analysis 
(Shimadzu FTIR-8400S) by KBr pellet technique at 4000 to 
400 to cm-1, with a resolution of 4 cm-1.  
2.3. Fabrication of CS/MMT Nanospheres 
Spherical nanoparticles were fabricated with 
electrospraying method. Prior to drug loading, 2-level-full 
factorial design was performed to determine the main effect 
of process parameters and their two- and three-way 
interactions on the output response (nanosphere diameter) by 
Minitab® software. Factorial design was selected due to 
minimize the total number of experiments to achieve the 
most precise overall optimization 11. The effect of process 
parameters was investigated by altering the voltage (10 and 
20 kV), distance (5 and 10 cm) and the flowrate of the 
polymeric solution (5 and 10 mL/h). Needle diameter (1.27 
mm) and the polymer concentration (2% w/v) were kept 
constant in order to avoid fiber formation. The acetic acid 
concentration of the solution was kept constant at 90% (v/v) 
since this concentration was found as optimal to decrease the 
surface tension of the chitosan solution and increases the 
charge density of jet 12. The collector surface was covered 
with aluminum foil and the product was collected on surface. 
Experiments were randomly replicated as thrice. Then, the 
morphology and the size of fabricated nanospheres were 
analyzed by SEM analysis. In each sample, the diameter of 
minimum 250 nanospheres was measured by ImageJ 
software to determine the average size. 
After optimizing the electrospraying parameters, 
Vancomycin (VC) and Gentamicin (GC) were added to 
CS/MMT solutions before microfluidizer homogenization 
with a polymer to drug weight ratio (P:D) of 4:1, 8:1 and 
10:1, 20:1 for VC and GC antibiotics, respectively. Drug 
incorporated solutions were homogenized with MF under 
working conditions of 10,000 psi pressure and 5 passes 
according to nanocomposite characterization tests. The 
microfluidized solutions were electrosprayed with a voltage 
of 20 kV, a distance between syringe and collector of 10 cm 
and 5 mL/h flowrate to fabricate spherical nanoparticles. 
Figure 1 shows the schematic diagram of homogenization 
and electrospraying process. 
 
 
Figure 1. The schematic diagram of microfluidizer and electrospraying unit 
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2.4. Characterization of drug loaded CS/MMT 
nanospheres 
SEM analysis was performed in order to observe the 
morphology of the nanospheres with Quanta FEG 250 (at 
7x10-2 mbar and 15 mA). Before the analysis, samples were 
coated with a thin gold layer under argon gas (Emitech 
K550X). The size distribution of the nanospheres was 
determined with the Dynamic Light Scattering (DLS) 
analysis. The samples were suspended in 5 mL of 1x 
phosphate buffer saline (PBS) and pH was adjusted to 7.4 at 
25°C, sonicated for 5 minutes to prevent aggregation, 
decanted into a glass scintillation vial and analyzed by 
Malvern Zetasizer Nano-Zs. The particle size distribution 
and mean hydrodynamic diameters were analyzed as 
intensity averaged distributions. The experiments were 
conducted thrice, and the results were given as the average of 
3 runs and 100 scans for each run. 
The zeta potential of the nanospheres were analyzed with 
Malvern Zetasizer Nano-Zs. Samples (n=3) were analyzed in 
1x PBS (pH=7.4) and ultrapure water at 25°C. Samples were 
dispersed in liquid media, vortexed and analyzed with 3 runs 
and 100 scans per one run. The point of zero charge (PZC) of 
MMT nanoclay dispersion in 1x PBS was determined by 
altering the pH between 3 and 12. The pH of the nanoclay 
dispersion was adjusted by using buffer solutions of 0.1M 
HCl and 0.1M NaOH.  
The chemical interactions between drugs and the 
nanocomposite matrix were determined with FT-IR 
(Shimadzu FTIR-8400S) analysis at 4000 to 400 to cm-1, 
with a resolution of 4 cm-1. 
In order to calculate the encapsulation efficiency, 
nanospheres were dissolved in 5 mL of 1x PBS (pH=7.4) and 
disrupted in an ultrasonic bath for 30 minutes. The solution 
was filtered, and the amount of entrapped drug was 
determined by UV-Vis spectroscopy (Varioskan) according 
to the previously determined calibration curve. The 
absorbances of the samples were measured at 256 and 282 
nm for GC and VC, respectively. Encapsulation efficiency of 
was calculated according to the equation below (Equation 1): 
EE (%) = (Amount of drug/Theoretical amount of drug) x100 
2.5. In vitro drug release 
In vitro VC and GC release from CS and CS/MMT 
nanocomposites was determined under immersion 
conditions. Samples (n=3) were placed in 1x PBS (pH=7.4) 
and incubated in an orbital shaker at 75 rpm and constant 
temperature of 37°C. Release media were collected at 
predetermined time intervals and replaced with fresh PBS. 
The volume of the incubation medium was kept constant 
during the analysis. The release rate was determined with 
absorbance data taken by UV-VIS spectroscopy (Varioskan). 
Furthermore, the drug release profiles were fitted to the First-
order, Higuchi, Hixson-Crowell and Baker-Lonsdale kinetic 
models. Then, Korsemeyer-Peppas model was applied to 
understand the underlying mechanism in release of 
antibiotics13. 
2.6. Antimicrobial activity 
Gram-positive Staphylococcus aureus (RSKK 1009) and 
gram-negative Escherichia coli (ATCC® 25922) were used 
as model organisms for antimicrobial activity tests. The 
frozen bacteria stocks were activated at 37ºC overnight prior 
to experiments. 3.4x107 cfu mL-1 of early mid-log phase 
culture of S. aureus in tryptic soy broth and 2.5x107 cfu mL-1 
of E. coli in nutrient agar were incubated at 37°C for 24 h.  
Firstly, the bacteria cultures were incubated with serially 
diluted antibiotic solutions for 24 h of incubation in 6-well 
plates in an orbital shaker at 55 rpm and 37°C to observe 
whether the concentration of released antibiotic is sufficient 
to prevent the bacterial colonization. Then, the bacteria 
solution containing antibiotics were placed on agar and 
incubated at 37°C for 24 h. The minimum required drug 
concentration was determined by observation of bacteria 
colonization on petri dishes. 
The antimicrobial activity of drug release media of 
CS/MMT nanospheres was evaluated with the agar diffusion 
method. The antimicrobial susceptibility discs (Oxoid™) 
were gently put on the surface of inoculated agar with 
bacteria. 10 µl of drug release media taken at specified time 
intervals (6 hours, 24 hours and 25 days) were dropped on 
discs (n=3). Vancomycin and amoxicillin antibiotic discs 
were used as positive; blank disk was used as a negative 
control. Petri dishes were incubated at 37°C overnight and 
the clear zones around the discs were recorded after 1 day of 
incubation. 
2.8. Statistical analysis 
The significance of the differences between the results 
was evaluated by one-way and two-way analysis of variance 
(ANOVA) with P<0.05 as a minimum level of significance. 
The statistical analysis was performed using GraphPad Prism 
7.0 (GraphPad Software Inc.). All experiments were 
conducted as three replicates and the results were expressed 
as a mean ± standard deviation. 
3. Results 
3.1. Nanocomposite Characterization 
XRD study was performed to display the clay distribution 
level in the polymer matrix. Figure 3 depicts the XRD 
pattern of the chitosan (CS), montmorillonite (MMT) and 
CS/MMT composites homogenized with 10,000 psi pressure 
and pass number of 3 and 5. The characteristic peak was 
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depicted in 2θ=20.7° due to diffraction of chitosan powder, 
which well agrees with the previous reports14. In a study, it 
was observed that the characteristic peak for pristine 
nanoclay at 2θ=7° shifted to small angles with increasing the 
chitosan content due to intercalation8. Similarly, the 
diffraction peak of MMT (Cloisite 10A) was observed 
approximately in 2θ=7.23°. According to the Bragg’s law, 
the peak at 7.23° indicates a basal d-spacing of 12.22Å. This 
peak has shifted left to 6.78° with a microfluidizer 
application of 10,000 psi and 3 passes due to the intercalation 
of MMT layers. It was calculated that the d-spacing value 
increased to 13.03Å, which is a sign of an intercalated 
structure 15. The permeation of chitosan into MMT galleries 
broadened the layer spacing. Two hydroxyls and one amino 
functional group of chitosan can provide an interaction 
between hydroxyl edges of MMT layers by hydrogen 
bonding to ensure the penetration into MMT nanosheets16. 
Cyclic microfluidizer application with 5 pass at 10,000 psi 
caused exfoliation of the single clay layers in the polymer 
matrix. Furthermore, the characteristic peak of MMT could 
not be observed in 2θ range of 3-9° at 5 passes of MF 
application that indicates the exfoliated structure17. STEM 
images also showed that MMT was effectively dispersed in 
polymer matrix. Layered structures of MMT were observed 
clearly with 25000x, 50000x, 100000x and 200000x 
magnifications (Figure 2 a,b,c,d). MMT particles were 
dispersed as both intercalated and exfoliated structures in 
chitosan matrix. MMT particle size range was obtained 
between 180-400 nm in thickness and 700-1300 nm in width.  
Therefore, microfluidizer working conditions were 
determined as 10,000 psi and 5 passes to enrich exfoliated 
structure for antibiotic loaded nanospheres to achieve 
sustained drug release. 
 
 
 
Figure 2. STEM images of CS/MMT nanocomposite 
 
 
Figure 3. XRD spectra of chitosan (CS), montmorillonite 
(MMT) and microfluidized CS/MMT nanocomposites 
 
FT-IR analysis was performed to determine the functional 
groups of chitosan, MMT nanoclay and CS/MMT 
nanocomposites (Figure 4). The FT-IR spectrum of chitosan 
consists of characteristic bands appeared at 1655 cm-1 (C=O 
stretching of amide I), 1560 cm-1 (N-H bending of amine) 
and 1380 cm-1 (C-N stretching and N-H bending of amide 
linkages). The main characteristic peaks of MMT are at 3667 
cm-1 (Al-OH stretching), 1020 cm-1 (Si-O stretching), 913 
cm-1 (Al-Al-OH). The peaks of number 5 (-CH- stretching) 
and 6 (-CH2 vibration) were located on MMT spectra due to 
the organic modification18. In the case of CS/MMT 
composite groups, the IR spectra showed that the 
characteristic bands of both CS and MMT that appeared in 
the CS/MMT composite. The characteristic amide I (1655 
cm-1), amine (1560 cm-1) and amide III (1380 cm-1) peaks of 
chitosan slightly shifted to left in CS/MMT composite. The 
characteristic band of MMT due to -CH2 vibration (2916 cm-
1) was seen in the CS/MMT composite. The interaction of CS 
and MMT was ensured by the hydrogen bonding due to 
hydroxylated silicates of MMT and, amino and hydroxyl 
groups of CS15. The MMT Si-O stretching (1020 cm-1) was 
overlapped with CS peaks in the IR spectra of CS/MMT 
group. The peak at 2990 cm-1 due to OH stretching was 
shifted to 2934 cm-1 and overlapped with the characteristic 
peak of MMT due to -CH2- vibration at 2916 cm-1. The 
intensities of the characteristic peak of MMT due to Al-OH-
Al stretching (913 cm-1) and -CH- bending (2852 cm-1) were 
decreased in composite groups when compared to pure 
MMT. This fact also confirms the interaction between 
chitosan and MMT19.  
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Figure 4. IR spectrum of chitosan, MMT and CS/MMT 
composite groups 
3.2. Optimization on Electrospray Process Parameters 
The effect of electrospray parameters on nanosphere 
formation were investigated by measuring the nanosphere 
sizes from images taken by SEM analysis (Figure 6). 
The main and interactive effects of experimentally 
controlled factors like voltage, distance and flowrate on the 
response (particle diameter) were investigated through the 23 
two-level full factorial design. The independent variables and 
the ranges were tabulated in Table 1. The size of nanosphere 
samples in each run was given in Table 2.  
The experimental results were analysed with Minitab 
software and the main effects on average nanosphere 
diameter were shown in Figure 5.a. Results implied that 
smaller nanosphere size could be achieved with higher 
voltage, higher distance and lower flowrate. It was inferred 
that each main effect significantly affects the response 
(Figure 5.b).  
 
Table 1. Factors and levels for the electrospraying process 
Independent 
variable 
Coded 
Symbol 
Range and level 
Low (-1) High (+1) 
Voltage (kV) A 10 20 
Distance (cm) B 5 10 
Flowrate (mL/h) C 5 10 
 
Table 2. Complete design layout of 3 factors, 2-level full 
factorial design and the response obtained from randomly 
performed experiments 
Std. 
order 
Run 
order 
Group 
codes 
Coded 
values of 
independent 
variables 
Response 
Nanosphere 
diameter(nm) 
A B C 
1 4 A - - - 127.04±7.7 
2 6 B - - + 141.75±4.0 
3 3 C - + - 87.67±2.1 
4 5 D - + + 104.73±5.1 
5 7 E + - - 111.75±4.7 
6 1 F + - + 116.91±2.0 
7 8 G + + - 86.67±3.5 
8 2 H + + + 96.45±4.0 
 
Therefore, ANOVA was done with 95% two-sided 
confidence interval to evaluate the significance of the effects 
and the interactions among the variables. It was observed that 
besides main effects, two-way interactions of voltage-
distance and voltage-flowrate also affected the size of 
nanospheres. However, two-way interactions of distance and 
flowrate, and the three-way interaction were not statistically 
significant. The analysis of variance for nanosphere 
diameters with significant terms is given in Table 3. 
The uncoded mathematical model for 23 factorial design 
after discarding insignificant terms can be represented as: 
 
D (nm) = 171.4 – 2.667A – 10.77B + 4.97C + 0.3133AB – 0.18AC 
 
where D is diameter of the nanospheres. The factorial 
regression model showed a high regression coefficient (R2) 
in the determined range as 0.958. 
As a result of the statistical design of the electrospray 
parametric optimization experiments followed by regression, 
electrospray parameters were set as a voltage of 20 kV, a 
distance of 10 cm and a flowrate of 5 mL/h that results with 
uniformly distributed nanospheres with the smallest size and 
spherical shape.  
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 Figure 6. Electrosprayed chitosan particles (Groups codes were depicted in Table 2.) 
 
Table 3. Analysis of variance for nanosphere diameter 
Source Df Sum of squares Mean square F value p-value 
Model 5 7743.6 1548.73 81.95 <0.0001 
Voltage 1 962.67 962.67 50.94 <0.0001 
Distance 1 5520.67 5520.67 292.13 <0.0001 
Flowrate 1 770.67 770.67 40.78 <0.0001 
Voltage*Distance 1 368.17 368.17 19.48 <0.0001 
Voltage*Flowrate 1 121.50 121.50 6.43 0.021 
Residual 18 340.17 18.90   
Total 23 8083.83    
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Figure 5. Main effects for nanospheres diameter  
(a); Pareto chart for standardized effects (α=0.05) (b). 
3.3. Characterization of the VC and GC Loaded 
CS/MMT Nanospheres 
According to the SEM images and hydrodynamic size 
distributions, it can be observed that selected electrospray 
parameters were suitable for nanosphere formation since the 
formed nanoparticles showed a smooth surface and perfectly 
spherical shape (Figure 7). The size distribution of 
nanospheres dispersed in 1x PBS (pH=7.4) was tabulated and 
given by intensity % (Table 4). Low polydispersity index 
(PDI) values (<0.2) shows the homogeneity of the system 
with a narrow size distribution. The average hydrodynamic 
size of CS/MMT nanospheres was found as 65.2±4.3 nm. 
DLS results indicated that hydrodynamic size increases with 
drug incorporation when compared to the control, i.e. 
unloaded, CS/MMT nanospheres. The mean hydrodynamic 
size was found as 351±20.18 nm and 210±19.25 nm for the 
groups having chitosan to Vancomycin ratio of 4:1 and 8:1, 
respectively. The mean hydrodynamic sizes of Gentamicin 
loaded nanospheres were found as 246.4 nm and 181.6 nm 
for the groups having P:D of 10:1 and 20:1, respectively.  
 
 
Figure 7. SEM images and intensity based hydrodynamic 
size distributions of CS/MMT (a), CS/MMT-VC (4:1) (b), 
CS/MMT-VC (8:1) (c), CS/MMT-GC (10:1) (d) and 
CS/MMT-GC(20:1) (e) nanospheres (Scale bars represent 2 
μm). 
 
The point of zero charge (PZT) of MMT nanoclay was 
found in pH 6.2 (Figure 8). In literature, it was indicated that 
the PZC of MMT varies between 6.4 – 7.2 20. The zeta 
potential of MMT varied at different pH values due to the 
proton adsorption or desorption on the edge -OH- groups and 
isomorphous substitutions at the faces of platelets21. The 
amphoteric parts were positively or negatively charged due 
to the pH of the media. Some parts of cations do not strongly 
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hold to the structure hence readily exchanged by other ions. 
Therefore, it can be inferred that particle stability is assured 
by homogeneous dispersion of negatively charged MMT in 
positively charged CS matrix in the pH of the body fluid. 
Moreover, the zeta potential of nanospheres was measured 
immediately after suspended in ultrapure water and PBS 
(Table 4). The zeta potential of CS/MMT nanospheres were 
found higher in ddH2O when compared to PBS. The 
continuous dissolution of atmospheric CO2 lead to pH 
reduction in water that paves the way for protonation of 
amine groups of chitosan22. Therefore, relatively positive 
zeta potential values were observed. It was found that 
prepared CS/MMT nanospheres are positively charged due to 
the polycationic nature of chitosan. The zeta potential of neat 
CS nanospheres was found in a range of 24-29 mV. 
However, the zeta potential of neat CS/MMT nanospheres 
was measured as 13.3-18.7 mV due to the negative charge of 
MMT nanoclay in the working pH. Hence, prepared drug 
loaded nanospheres carried their stability in aqueous media 
according to their repulsive forces. 
All antibiotic loaded nanospheres showed a positive zeta 
potential that indicates electric repulsion preventing 
aggregate formation. In addition, positive surface charge is 
advantageous in antibiotic delivery systems since most of the 
bacterial cellular membrane surfaces are negatively 
charged23.  
 
 
Figure 8. The zeta potential of MMT in various pH 
 
Additionally, chemical interactions between the 
antibiotics and CS/MMT nanocomposite were analyzed with 
FT-IR analysis. Figure 9.a depicts the IR spectra of the 
CS/MMT, Vancomycin and the Vancomycin-loaded 
CS/MMT groups. Vancomycin has a characteristic 
absorption band of -OH- stretching (3450 cm-1), C=O 
stretching (1652 cm-1), aromatic C=C stretching (1502 cm-1) 
and phenolic groups (1232 cm-1)24,25. The existence of most 
of these bands confirmed the presence of Vancomycin in the 
nanocomposite spheres. 
 The interaction between the polymer matrix and 
Vancomycin was supported with hydrogen bonds (3750-
2250 cm-1) and observed as a shifted and broadened band.  
The FT-IR spectra of CS/MMT, Gentamicin and 
Gentamicin-loaded CS/MMT groups with a polymer to drug 
ratio of 10:1 and 20:1 were depicted in Figure 9.b.  In 
literature, it was indicated that the Gentamicin spectra 
includes a strong absorption band due to stretching vibrations 
of C-N and C-O between 1300-900 cm-1; N-H vibration at 
1650-1400 cm-1 26. Most of the characteristic peaks of 
Gentamicin were depicted in the IR spectra of Gentamicin 
incorporated groups. The Gentamicin incorporation into 
CS/MMT matrix can be explained by hydrogen bonding due 
to shifts of amide I and II groups of the CS. The intensity of 
the hydroxyl peak (3420 cm-1) was weakened and broadened 
in Gentamicin loaded CS/MMT matrix. This change was 
linked with the merge of chitosan and gentamicin -OH- 
bending at 3415 cm-1 22,27. 
The structure of the carrier matrix and the polymer to drug 
ratio (P:D) are known as significant factors affecting the drug 
release rate and the drug encapsulation efficiency (EE%) of 
the polymeric carrier material. It was observed that the 
nanocomposite formation significantly increased the 
encapsulation efficiency (Table 5). The nanocomposite 
structure improved the Vancomycin entrapment of the matrix 
from 80 to 86% without changing the P:D ratio. Similarly, 
Gentamicin incorporation was significantly increased from 
76 to 94% by aid of exfoliated nanocomposite matrix. The 
entrapment efficiency of Vancomycin loaded groups were 
found as 79.04 and 86.56% for the P:D of 4:1 and 8:1, 
respectively. The incorporation of the drug into the polymer 
matrix becomes easier as P:D increases, which results in 
higher entrapment efficiency value. Similar findings were 
also observed in the literature regarding polymeric 
nanoparticulate drug delivery systems27,28. Similarly, the 
entrapment efficiencies of Gentamicin loaded groups were 
found as 90.59 and 94.73% for the P:D of 10:1 and 20:1, 
respectively.  
 
Table 3. Encapsulation efficiencies of drug loaded 
nanospheres 
Material Drug Polymer:Drug 
Encapsulation 
efficiency (%) 
CS 
VC 
8:1 80±3 
CS/MMT 4:1 79±1 
CS/MMT 8:1 87±3 
CS 
GC 
20:1 76±2 
CS/MMT 10:1 91±5 
CS/MMT 20:1 95±4 
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Table 4. Zeta potential and hydrodynamic size distributions of nanospheres 
Groups 
Zeta Potential (mV) DLS Measurements (in PBS) 
in PBS in ddH2O Average size (nm) PDI 
CS/MMT 13.3±1.26 18.7±0.06 65.2±4.3 0.09 
CS/MMT-VC (4-1) 5.6±0.21 8.2±1.12 351±20.2 0.11 
CS/MMT-VC (8-1) 12.3±1.72 17.4±2.30 210±19.3 0.16 
CS/MMT-GC (10-1) 4.3±0.03 7.8±1.48 246.4±19.3 0.14 
CS/MMT-GC (20-1) 6.9±0.55 9.9±0.78 181.8±22.1 0.18 
 
 
Figure 9. IR spectrum of Vancomycin (a) and Gentamicin 
(b) loaded nanospheres. 
3.4. In vitro drug release  
The in vitro Vancomycin and Gentamicin release over 
time were identified to evaluate the feasibility of CS/MMT 
nanocomposites as a long-term local drug delivery system. In 
literature, it was observed that incorporation of layered clay 
minerals in chitosan coating on titanium implants can 
prolong the release of Vancomycin from few days to month 
and decrease the burst release29.  
The cumulative drug release profiles of Vancomycin and 
Gentamicin drugs with two different P:D ratio was given in 
Figures 10 a,b respectively. As seen in the cumulative plots, 
two-step release profile was observed as an initial burst and 
sustained release in nanocomposite groups.  
In the control group, i.e. without MMT nanofiller 
addition, the release could only be tracked for few hours. In 
order to increase the stability of the chitosan nanocarriers, 
here we have examined the effect of MMT nanofiller in the 
chitosan matrix as a nanocomposite structure. The 
Vancomycin release in neat CS nanospheres could only be 
monitored for 4 hours of incubation with a burst release 
profile about 100% whereas the drug release was sustained 
up to 30 days with a nanocomposite structure.  
In composite groups, the burst release in 6 hours was 
followed by a controlled release profile. 38±1.86% of 
Vancomycin has released from CS/MMT-VC (4:1) 
nanospheres in first 6 hours, followed by a controlled release 
of 88±1.53% of the total amount of drug until it reaches a 
plateau. Finally, 96±1.15% of the Vancomycin was released 
to the incubation media. It was observed that nanospheres 
containing less amount of Vancomycin (CS/MMT-VC (8:1)) 
showed a slower release rate when compared to CS/MMT-
VC (4:1) group. 24±0.58 % of GC release in 6 hours is 
followed by a controlled release. Finally, 96±1.15% of the 
Vancomycin released to the incubation media.  
By evaluating the release pattern shown in Figure 9, neat 
CS nanocarriers could entrap the hydrophilic Gentamicin 
only for 4 hours. On the other hand, the release was 
prolonged up to 30 days with the nanocomposite structure. 
84 and 88% of the drug released from CS/MMT-GS (20:1) 
and CS/MMT-GS (10:1) nanospheres in 30 days, 
respectively. Similarly, the decrease in release rate was 
observed when P:D ratio was increased. CS/MMT 
nanospheres that contain less amount of drug decelerated the 
burst release effect by entrapping the drug stronger inside the 
polymer matrix. Relatively linear trend was observed for 
CS/MMT-GC 10:1 group after the burst release until it 
reaches the plateau on the 20th day. CS/MMT-GC (20:1) 
group showed a biphasic trend due to possible degradation of 
nanospheres at day 14. 
It was reported that the minimum Gentamicin 
concentration should be in 1-10 ng/mL at the defect site to 
promote bone healing30. The results showed that the 
therapeutic drug level was achieved without exceeding the 
toxic concentration. 
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Figure 10. The cumulative release of Vancomycin (a) and Gentamicin (b) from CS and CS/MMT nanospheres 
 
Mathematical relations corresponding the drug release 
during incubation were evaluated to predict the release rate at 
the specified time. Therefore, First-order, Higuchi, 
Korsmeyer-Peppas, Hixson-Crowell and Baker-Lonsdale 
empirical models were applied to determine the release 
kinetics and the dominant mechanism of Vancomycin and 
Gentamicin release from CS/MMT nanospheres. The initial 
porosity of the nanocomposite matrix was assumed 
negligible for Baker-Lonsdale model. 
Mathematical models were applied to the experimental 
data and the release coefficients (k), Korsmeyer-Peppas 
release exponent (n) and the correlation coefficients (R2) 
were depicted in Table 6. The optimum model was selected 
according to the correlation coefficient values. 
For Vancomycin-loaded nanospheres, it was found that 
the best fitting model is Higuchi based on the data presented 
in Table 6. The model claims the release of Vancomycin 
from nanocomposite matrix is a time-dependent process 
based on Fickian diffusion where the drug reservoir does not 
dissolve during the release31.  
For Gentamicin loaded groups, the best model was found 
to be Baker-Lonsdale, the model developed from Higuchi 
especially for spherical drug carrier systems32.  
Furthermore, first 60% of drug release data were fitted to 
Korsmeyer-Peppas model and “n” value was used to 
characterize the release mechanism. It was found that each 
system has “n” value below 0.45 indicating that Fickian 
diffusion is the main mechanism in drug delivery from 
spherical CS/MMT nanocomposites33. In literature, chitosan 
based particulate nanocomposite systems followed Fickian 
diffusion mechanism for release of Repaglinide which shows 
diffusion of dissolved drug across the matrix that 
mechanically enhanced with cellulose nanocrystals34.  
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Table 5. Release kinetic coefficients for CS/MMT nanospheres. 
Models  
Vancomycin Gentamicin 
4:1 8:1 10:1 20:1 
First order 
K 0.003 0.004 0.002 0.002 
R2 0.909 0.954 0.809 0.806 
Higuchi 
k 2.470 3.037 1.935 2.170 
R2 0.935 0.992 0.885 0.878 
Hixson-Crowell 
K -0.007 -0.004 -0.002 -0.002 
R2 0.859 0.979 0.853 0.767 
Baker-Lonsdale R2 0.931 0.962 0.938 0.833 
Korsmeyer-Peppas 
n 0.193 0.238 0.215 0.191 
R2 0.922 0.996 0.952 0.802 
 
Table 6. Effect of in vitro release media (6 h, 24 h, 25 days) against E. coli and S. aureus 
 Inhibition zone of E. coli (mm) Inhibition zone of S. aureus (mm) 
Groups 6 hours 24 hours 25 days 6 hours 24 hours 25 days 
(+) control 1 
(Amoxycylin) 
10±0.00 6±0.00 
(+) control 2 
(Vancomycin) 
5±0.00 11.3±0.01 
(-) control (Blank) - - 
CS/MMT-VC (4:1) 14±0.00 11.3±0.01 10.0±0.01 7.9±0.01 5.3±0.03 5.3±0.03 
CS/MMT-VC (8:1) 14.7±0.01 10.7±0.01 9±0.00 5.5±0.01 4.8±0.02 4.4±0.02 
CS/MMT-GC (10:1) 14.7±0.02 10.0±0.01 10.3±0.01 2.8±0.01 4±0.00 3.1±0.01 
CS/MMT-GC (20:1) 11.7±0.02 9.7±0.01 8.8±0.00 3.8±0.01 4.1±0.01 3.8±0.01 
 
3.5. Antimicrobial activity 
To confirm the relevance of the in vitro release study, the 
antimicrobial activity of the release media was investigated 
for Gram-positive S. aureus and Gram-negative E. coli. The 
minimum inhibition concentration of selected antibiotics on 
selected bacteria were determined with serial dilution tests 
(Figure 11). According to results, 0.25 mg/L of Vancomycin 
and Gentamicin was enough to inhibit bacteria colonization. 
On the other hand, S. aureus colonization was prevented with 
2 mg/L of Gentamicin or 0.75 mg/L of Vancomycin. The 
results showed that released drug concentrations in all time 
intervals were higher than MIC values ensuring the 
antimicrobial activity. Therefore, it could be claimed that the 
therapeutic drug level can be achieved with the developed 
nanocomposite system without exceeding the toxic 
concentration. 
Inhibition zones were clearly observed on discs diffusing 
the release media of nanospheres taken at specific time 
intervals (6 hours, 24 hours and 25 days). In negative control 
(blank disc), no inhibition zone was observed. Effect of 
released drugs against E. coli and S. aureus were observed as 
clear zones after 24 hours of incubation depicted in Figure 
12. The inhibition zones were given in Table 7.  
It can be observed that the antimicrobial activity against S. 
Aureus was slightly increased with the increase in drug 
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concentration which may be due to the increased drug 
penetration to bacterial cell wall. In addition, the inhibition 
zone at the 6 h period was larger, which is attributed to the 
burst release in short-time period. Similarly, Ryu et al. 
(2014) studied the effect of release kinetics on the 
antimicrobial activity of Gentamicin releasing PCL 
microspheres against S. aureus and E. coli. It was indicated 
that larger inhibition zones were achieved in the groups 
having burst drug release35. Similarly, Ambrogi et al. (2017) 
observed that MMT incorporation in chitosan based films 
caused slightly lower antimicrobial activity due to slower 
antibiotic release caused by intercalation of drugs into clay 
layers36. 
During the antimicrobial activity tests, optimum 
conditions (pH, medium composition and temperature) for 
the proliferation of the test microorganisms were supplied. 
Consequently, higher antimicrobial activity is expected in the 
real case since pure strains cultured in laboratory conditions 
show maximum growth. 
  
 
Figure 11. Minimum Inhibitory Concentration (MIC) determination of Vancomycin Hydrochloride and Gentamicin 
Sulphate by serial dilution test. 
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Figure 12. Effect of release media against E. coli and S. Aureus at incubation times of 6h, 24h and 25 days. 
 
3.6. In vitro cytotoxicity 
Cytotoxicity of the nanospheres on NIH/3T3 and SaOS-2 
cell lines was evaluated by 24 h extraction of nanospheres in 
24, 48 and 72 hours of incubation and depicted in Figure 
13(a,b) respectively. It was observed that nanospheres did 
not cause any cytotoxic effect on cells. Indeed, all groups 
showed good viability (>95%). Statistically, drug loaded 
nanospheres showed significant viability increase in 
incubation time for both cell line (P<0.05). In some groups, 
non-significant viability decrease at 72 hours of incubation 
was observed according to the possible contact inhibition of 
cells.  Previous studies showed that CS/MMT composites do 
not show any cytotoxic behavior also to Caco-2 cells and rat 
stem cells37,38. 
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Figure 13. In vitro cytotoxicity of nanospheres against 
NIH/3T3 (a) and SaOS-2 (b) cell lines 
 
4. Discussion 
Infection is one of the most serious drawbacks of bone 
implantation operations which can cause necrosis of the 
tissue. Therefore, two weeks of antibiotic treatment is 
recommended in general as a precaution to eliminate the risk 
of possible infections39. Sustained antibiotic delivery is 
needed at the implant site to guarantee the prevention from 
microbial contamination of the implant. 
One of the most challenging point in long-term drug 
delivery applications is to ensure the stability of the carrier 
during the treatment period and to ensure that it is degraded 
into non-toxic monomers after it releases the cargo. Besides 
its peculiar properties over other polymers for drug delivery 
applications, the poor stability of chitosan restricts its 
practical applicability in long-term release systems40. 
Nanocomposite systems can be considered as a solution to 
overcome disadvantages of biopolymer-based systems as 
well as improving mechanical and barrier properties even at 
very low concentrations compared to conventional 
composites that needs 40-50 wt. % fillers41. Recently, 
polymer-montmorillonite (MMT) nanocomposites have been 
used in pharmaceutical applications to improve drug 
bioavailability by changing the release rate or distribution of 
cargo in carrier matrix42. This control over release profile can 
minimize the side effects of drugs, such as toxicity, and 
provides a therapeutic concentrations of drug in treatment 
period36. In this study, fabricated CS/MMT nanospheres 
combines several advantages to achieve controlled antibiotic 
release at the defect media. The exfoliated nanocomposite 
structure prolongs the stability of drug carrier in 
physiological conditions since it serves a tortuous pathway to 
the drug for diffusion. MMT nanosheets can act as a cross-
linker to ensure stability and slower release rate of 
hydrophilic drugs. The hydrophilic and cationic nature of the 
chitosan facilitates intercalated/exfoliated CS/MMT 
nanocomposite structure by cyclic application of high-
pressure homogenizer. 
After nanocomposite formation, it was aimed to achieve 
nano-scale particles with spherical shape and smaller size. 
Morphology and the homogenity in the particle size are 
critical parameters for drug carrier materials to predict the 
release pattern more precisely. In this study, one-step 
electrospraying was selected as a production method to 
achieve higher yield compared to other production 
techniques. However, the disability of size control during 
operation yield us to make an experimental design to find the 
effect of process variables on nanosphere size. According to 
results, a voltage of 20 kV, distance of 10 cm and a flowrate 
of 10 mL/h was selected as optimum conditions to achieve 
smaller nanospheres with uniform size. A mathematical 
model was derived with a high regression coefficient (0.96) 
which can be further used to achieve nanocarriers with a 
desired size. Afterwards, characterizations were performed to 
observe the morphology and the hydrodynamic size 
distributions of the drug loaded nanospheres. Experimental 
results point out that the decrease in polymer to drug ratio 
(P:D) leads to formation of larger particles. The increase in 
nanosphere size can be attributed to the drug integration in 
the polymer matrix. Literature findings also support that 
drugs incorporation in polymer matrix increase the size of 
the carriers when compared to the neat carrier material 37. 
These results were found in good agreement with 
Vancomycin loaded CS microspheres and Gentamicin loaded 
CS nanoparticles in literature43,27.  
The zeta potential of the carrier material gives an insight 
about the stability of the system and has a major influence on 
release profile and circulation in the body fluid. The stability 
of the carrier material in a surrounding fluid is an important 
criterion to overcome the aggregate formation in 
nanoparticulate drug delivery systems. The stability of the 
nanoparticles was guaranteed by electrostatic interactions 
between CS and MMT since they show opposite charges in 
physiological conditions. 
Studies revealed that drug encapsulation efficiency 
strongly depends on the particle size, concentration of the 
active agent and the processing method44,45. According to the 
results, it could be concluded that the entrapment efficiency 
of the CS/MMT matrix was improved with the increase in 
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polymer to drug ratio (P:D). Prepared nanospheres showed 
high encapsulation efficiency (76-95%) which increases the 
applicability of the system. Therefore, the low efficiency of 
conventional drug administration methods could be 
overcome with presented carrier system entrapping the drug 
with a high efficiency and sustaining the release over time 
required for antibiotic treatments. The incorporation of the 
drug into the polymer matrix becomes easier as P:D 
increases, which results in higher entrapment efficiency 
value. 
The most important criterion for drug delivery system 
would be to supply therapeutic level of drug during 
treatment. Therefore, here we demonstrated that CS/MMT 
nanocomposites sustained the drug release for weeks 
whereas bare chitosan nanospheres were degraded in hours. 
MMT nanoclay acted as a barrier in the polymer matrix to 
decelerate the drug diffusion rate. This significant difference 
in release periods can be attributed to interactions between 
silicate layers with drugs and chitosan with Coulombic 
interactions, van der Waals fore and H- bonding5. 
In first 6 hours, burst release profile was observed due to 
possible diffusion of drug molecules adsorbed on nanosphere 
surface. This profile can be beneficial since most of the local 
infections after surgery occurs at this post-implantation 
period46. However, it is not enough to protect the defect 
region against bacterial inflammation. Studies indicated that 
biofilm formation can be seen at the tissue-material interface 
if long-term drug release cannot be achieved47. Therefore, 
initial burst release was followed by 30 days of sustained 
release period which was desired in the post-implantation 
period48. The developed two-step release model that diffuses 
drug in a controlled manner can be beneficial to overcome 
the local infection, then the gradual release of antibiotics 
prevents the bacterial recolonization.  
In chronic osteomyelitis, mostly described bacterial 
isolates are Staphylococcus species and Gram-negative 
bacteria. S. aureus is known as an important bone pathogen 
that causes bone destruction and failure in orthopedic 
implants49. In addition, it was reported that total knee 
replacement operations can result in a bacterial infection 
caused by E. coli50. Local Vancomycin and Gentamicin 
release is selectively used in bone infection cases for both 
Gr(+) and Gr(-) bacteria. It is known that intercalation of 
antibiotics into clay layers does not change the antimicrobial 
activity51. In the presented system, it was indicated that 
released Gentamicin and Vancomycin locally affected both 
pathogens which shows the availability of the prepared 
nanospheres as effective drug therapy. CS/MMT composite 
itself might promote the antibacterial activity with its 
bactericidal effect against E. coli52.  
Besides its strong antibacterial properties, in vitro 
cytotoxicity analysis suggested that fabricated CS/MMT 
nanospheres are cytocompatible with fibroblast and human 
osteoblast-like cell lines, which makes them an ideal 
candidate for antibiotic delivery agents in bone infection 
treatment. 
5. Conclusion 
In this study, controlled antibiotic releasing 
chitosan/montmorillonite (CS/MMT) nanocomposite spheres 
were fabricated to improve antimicrobial efficacy while 
reducing the systemic toxicity of the antibiotics. MMT 
nanoclay was implicated in chitosan matrix with 
microfluidizer homogenization to prolong the drug diffusion 
pathway and ensure the stability of the system. Drug loaded 
CS/MMT nanocomposites were obtained by electrospraying 
technique with a perfectly spherical shape in nano-scale. All 
groups obtain positive zeta potential due to the polycationic 
nature of chitosan. It was observed that drug entrapment 
capacity was increased by decreasing the loading amount. 
Initial burst release for 6 hours was achieved which is a 
critical period for bone infections. The drug release was 
proceeded in a controlled manner up to 30 days. It was found 
that Gentamicin and Vancomycin release from CS/MMT 
matrix were dominated by diffusion mechanism. In vitro 
release media of nanospheres showed strong antimicrobial 
activity against E. coli and S. aureus bacteria. In addition, 
fabricated CS/MMT nanocomposites did not show any 
cytotoxic effect against fibroblast and human osteoblast-like 
cells. The overall evaluations suggested that these antibiotic 
loaded CS/MMT nanospheres have a promising potential 
effect on bacterial infections at the post-implantation period. 
The antibiotic release from CS/MMT matrix can be 
controlled by alteration of polymer:drug ratio. Thus, high 
encapsulation efficiency and the sustained long-term release 
of these hydrophilic drugs make CS/MMT nanocomposite an 
ideal candidate to be used in nanoparticulate drug delivery 
systems. 
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